Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment
- PMID: 23995858
- DOI: 10.1158/1078-0432.CCR-12-3211
Long-term follow-up of MRC Myeloma IX trial: Survival outcomes with bisphosphonate and thalidomide treatment
Abstract
Purpose: Medical Research Council (MRC) Myeloma IX was a phase III trial evaluating bisphosphonate and thalidomide-based therapy for newly diagnosed multiple myeloma. Results were reported previously after a median follow-up of 3.7 years (current controlled trials number: ISRCTN68454111). Survival outcomes were reanalyzed after an extended follow-up (median, 5.9 years).
Experimental design: At first randomization, patients (N = 1,970) were assigned to bisphosphonate (clodronic acid or zoledronic acid) and induction therapies [cyclophosphamide-vincristine-doxorubicin-dexamethasone (CVAD) or cyclophosphamide-thalidomide-dexamethasone (CTD) followed by high-dose therapy plus autologous stem cell transplantation for younger/fitter patients (intensive pathway), and melphalan-prednisone (MP) or attenuated CTD (CTDa) for older/less fit patients (nonintensive pathway)]. At second randomization, patients were assigned to thalidomide maintenance therapy or no maintenance. Interphase FISH (iFISH) was used to analyze cytogenics.
Results: Zoledronic acid significantly improved progression-free survival (PFS; HR, 0.89; P = 0.02) and overall survival (OS; HR, 0.86; P = 0.01) compared with clodronic acid. In the intensive pathway, CTD showed noninferior PFS and OS compared with CVAD, with a trend toward improved OS in patients with favorable cytogenics (P = 0.068). In the nonintensive pathway, CTDa significantly improved PFS (HR, 0.81; P = 0.007) compared with MP and there was an emergent survival benefit after 18 to 24 months. Thalidomide maintenance improved PFS (HR, 1.44; P < 0.0001) but not OS (HR, 0.96; P = 0.70), and was associated with shorter OS in patients with adverse cytogenics (P = 0.01).
Conclusions: Long-term follow-up is essential to identify clinically meaningful treatment effects in myeloma subgroups based on cytogenetics.
Similar articles
-
Effects of induction and maintenance plus long-term bisphosphonates on bone disease in patients with multiple myeloma: the Medical Research Council Myeloma IX Trial.Blood. 2012 Jun 7;119(23):5374-83. doi: 10.1182/blood-2011-11-392522. Epub 2012 Apr 12. Blood. 2012. PMID: 22498739 Clinical Trial.
-
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial.Lancet. 2010 Dec 11;376(9757):1989-99. doi: 10.1016/S0140-6736(10)62051-X. Epub 2010 Dec 3. Lancet. 2010. PMID: 21131037 Free PMC article. Clinical Trial.
-
The role of maintenance thalidomide therapy in multiple myeloma: MRC Myeloma IX results and meta-analysis.Blood. 2012 Jan 5;119(1):7-15. doi: 10.1182/blood-2011-06-357038. Epub 2011 Oct 20. Blood. 2012. PMID: 22021371 Clinical Trial.
-
Bisphosphonates in multiple myeloma: a network meta-analysis.Cochrane Database Syst Rev. 2012 May 16;(5):CD003188. doi: 10.1002/14651858.CD003188.pub3. Cochrane Database Syst Rev. 2012. Update in: Cochrane Database Syst Rev. 2017 Dec 18;12:CD003188. doi: 10.1002/14651858.CD003188.pub4. PMID: 22592688 Updated. Review.
-
The clinical effectiveness and cost-effectiveness of bortezomib and thalidomide in combination regimens with an alkylating agent and a corticosteroid for the first-line treatment of multiple myeloma: a systematic review and economic evaluation.Health Technol Assess. 2011 Dec;15(41):1-204. doi: 10.3310/hta15410. Health Technol Assess. 2011. PMID: 22146234 Free PMC article. Review.
Cited by
-
Lenalidomide or bortezomib as maintenance treatment remedy the inferior impact of high-risk cytogenetic abnormalities in non-transplant patients with newly diagnosed multiple myeloma: a real-world multi-centered study in China.Front Oncol. 2023 Apr 20;13:1028571. doi: 10.3389/fonc.2023.1028571. eCollection 2023. Front Oncol. 2023. PMID: 37152063 Free PMC article.
-
Real world outcomes of lenalidomide or bortezomib maintenance in patients with multiple myeloma not undergoing stem cell transplantation.Ann Hematol. 2023 May;102(5):1171-1184. doi: 10.1007/s00277-023-05148-y. Epub 2023 Mar 8. Ann Hematol. 2023. PMID: 36882560
-
Geranylgeranyl diphosphate synthase: Role in human health, disease and potential therapeutic target.Clin Transl Med. 2023 Jan;13(1):e1167. doi: 10.1002/ctm2.1167. Clin Transl Med. 2023. PMID: 36650113 Free PMC article. Review.
-
A systematic review and meta-analysis of interventional studies of bisphosphonates and denosumab in multiple myeloma and future perspectives.J Musculoskelet Neuronal Interact. 2022 Dec 1;22(4):596-621. J Musculoskelet Neuronal Interact. 2022. PMID: 36458395 Free PMC article. Review.
-
The importance of retaining physical functions to prevent skeletal-related events in multiple myeloma patients with bone disease.EJHaem. 2022 Feb 28;3(2):480-483. doi: 10.1002/jha2.402. eCollection 2022 May. EJHaem. 2022. PMID: 35846024 Free PMC article.
Publication types
MeSH terms
Substances
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical